Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

HU-308: a potent and specific agonist at the peripheral cannabinoid receptor

Dec. 13, 1999

New cardiovascular gene therapy product appears to be safe in patients

Dec. 10, 1999

CV Therapeutics advances CVT-510 into phase II clinical trials

Dec. 10, 1999

Preparation and use of inhibitors of sodium-dependent Cl-/HCO3- exchange

Dec. 8, 1999

Chiron and Scios complete FGF agreement

Dec. 8, 1999

New cardioselective K(ATP) channel blocker inhibits ventricular fibrillation in ischemic rat model

Dec. 6, 1999

Highly potent inhibitor of PDGF-induced SMC proliferation discovered at Japan Energy

Dec. 3, 1999

Wakunaga identifies potent and selective chymase inhibitor

Dec. 3, 1999

Chiron and Searle plan pivotal phase III trial for sepsis compound

Dec. 3, 1999

Studies using new transgenic rat model illustrate role of CETP in atherosclerosis

Dec. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...